References
- Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest. 1970;49:673–8. doi:https://doi.org/10.1172/JCI106279.
- Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715–25.
- Pyzik M, Sand KMK, Hubbard JJ, Andersen JT, Sandlie I, Blumberg RS. The neonatal Fc receptor (FcRn): a misnomer? Frontiers in Immunology. Published online 2019 Jul 10.
- Huang C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY™ technology. Current Opinion in Biotechnology. 2009;20:692–99. doi:https://doi.org/10.1016/j.copbio.2009.10.010.
- Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Current Opinion in Biotechnology. 2011;22:868–76. doi:https://doi.org/10.1016/j.copbio.2011.06.012.
- Kuo TT, Aveson VG. Neonatal Fc receptor and IgG-based therapeutics. mAbs. 2011;3:422–30. doi:https://doi.org/10.4161/mabs.3.5.16983.
- Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. International Immunology. 2001;13:1551–59. doi:https://doi.org/10.1093/intimm/13.12.1551.
- Zhou J, Mateos F, Ober RJ, Ward ES. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J Mol Biol. 2005;345:1071–81. doi:https://doi.org/10.1016/j.jmb.2004.11.014.
- Petkova SB, Akilesh S, Sproule TJ, Christianson GJ, Al Khabbaz H, Brown AC, Presta LG, Meng YG, Roopenian DC. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol. 2006;18:1759–69. doi:https://doi.org/10.1093/intimm/dxl110.
- Dostalek M, Prueksaritanont T, Kelley RF. Pharmacokinetic de-risking tools for selection of monoclonal antibody lead candidates. mAbs. 2017;9:756–66. doi:https://doi.org/10.1080/19420862.2017.1323160.
- Tam SH, McCarthy SG, Brosnan K, Goldberg KM, Scallon BJ. Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities. mAbs. 2013;5:397–405. doi:https://doi.org/10.4161/mabs.23836.
- Haraya K, Tachibana T, Nanami M, Ishigai M. Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. Xenobiotica. 2014;44:1127–34. doi:https://doi.org/10.3109/00498254.2014.941963.
- Avery LB, Wang M, Kavosi MS, Joyce A, Kurz JC, Fan YY, Dowty ME, Zhang M, Zhang Y, Cheng A, et al. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies. mAbs. 2016;8:1064–78. doi:https://doi.org/10.1080/19420862.2016.1193660.
- Betts A, Keunecke A, van Steeg TJ, van der Graaf PH, Avery LB, Jones H, Berkhout J. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: a comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach. mAbs. 2018;10:751–64. doi:https://doi.org/10.1080/19420862.2018.1462429.
- Brambell FWR, Hemmings WA, Morris IG. A theoretical model of γ-globulin catabolism. Nature. 1964;203:1352–55. doi:https://doi.org/10.1038/2031352a0.
- Stein C, Kling L, Proetzel G, Roopenian DC, de Angelis MH, Wolf E, Rathkolb B. Clinical chemistry of human FcRn transgenic mice. Mamm Genome. 2012;23:259–69. doi:https://doi.org/10.1007/s00335-011-9379-6.
- Foote J, Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. Journal of Molecular Biology. 1992;224:487–99. doi:https://doi.org/10.1016/0022-2836(92)91010-M.
- Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clinical Therapeutics. 1999;21:309–18. doi:https://doi.org/10.1016/S0149-2918(00)88288-0.
- Klein-Schneegans AS, Kuntz L, Fonteneau P, Loor F. Serum concentrations of IgM, IgG1, IgG2b, IgG3 and IgA in C57BL 6 mice and their congenics at the lpr (lymphoproliferation) locus. Journal of Autoimmunity. 1989;2:869–75. doi:https://doi.org/10.1016/0896-8411(89)90013-9.
- Roopenian DC, Sun VZ. Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol. 2010;30:790–97. doi:https://doi.org/10.1007/s10875-010-9458-6.
- Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, et al. MHC class I-related neonatal Fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. Journal of Immunology. 2001;166:3266–76. doi:https://doi.org/10.4049/jimmunol.166.5.3266.
- Akilesh S, Christianson GJ, Roopenian DC, Shaw AS. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism. J Immunol. 2007;179:4580–88. doi:https://doi.org/10.4049/jimmunol.179.7.4580.
- Kobayashi K, Qiao S, Yoshida M, Baker K, Lencer WI, Blumberg RS. An FcRn-dependent role for anti-flagellin immunoglobulin G in pathogenesis of colitis in mice. Gastroenterology. 2009;137(1746–56.e1). doi:https://doi.org/10.1053/j.gastro.2009.07.059.
- Richter WF, Christianson GJ, Frances N, Grimm HP, Proetzel G, Roopenian DC. Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. mAbs. 2018;10:803–13. doi:https://doi.org/10.1080/19420862.2018.1458808.
- Liu X, Ye L, Christianson GJ, Yang J-Q, Roopenian DC, Zhu X. NF-kappaB signaling regulates functional expression of the MHC class I-related neonatal Fc receptor for IgG via intronic binding sequences. Journal of Immunology (Baltimore, Md: 1950). 2007;179:2999–3011. doi:https://doi.org/10.4049/jimmunol.179.5.2999.
- Guo J, Li F, Qian S, Bi D, He Q, Jin H, Luo R, Li S, Meng X, Li Z, et al. TGEV infection up-regulates FcRn expression via activation of NF-kappaB signaling. Sci Rep. 2016;6:32154. doi:https://doi.org/10.1038/srep32154.
- Cervenak J, Doleschall M, Bender B, Mayer B, Schneider Z, Doleschall Z, Zhao Y, Bősze Z, Hammarström L, Oster W, et al. NFkappaB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn. mAbs. 2013;5:860–71. doi:https://doi.org/10.4161/mabs.26507.
- Wang Y, Zhang WY, Hu S, Lan F, Lee AS, Huber B, Lisowski L, Liang P, Huang M, de Almeida PE, et al. Genome editing of human embryonic stem cells and induced pluripotent stem cells with zinc finger nucleases for cellular imaging. Circ Res. 2012;111:1494–503. doi:https://doi.org/10.1161/CIRCRESAHA.112.274969.